| 2025-06-25 |
复牌提示：
2025-06-24 19:50:00 停牌，复牌日期 2025-06-26 00:00:01
|
| 2025-06-16 |
详情>>
内部人交易：
Collier Kathryn J共交易3笔
|
| 2025-05-08 |
详情>>
股本变动：
变动后总股本6923.41万股
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.15美元,归母净利润-963.4万美元,同比去年增长-13.76%
|
| 2025-03-13 |
详情>>
业绩披露：
2024年年报每股收益-0.82美元,归母净利润-4635.8万美元,同比去年增长-54.34%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.63美元,归母净利润-3356.7万美元,同比去年增长-52.74%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.41美元,归母净利润-1950.5万美元,同比去年增长-37.83%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.29美元,归母净利润-846.9万美元,同比去年增长-18.63%
|
| 2024-04-19 |
股东大会：
将于2024-05-16召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for director named herein to serve until the next annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal;
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To indicate, on an advisory basis, the preferred frequency of holding stockholder advisory votes on the compensation of the Company’s named executive officers;
5.To approve an amendment to the Regulus Therapeutics Inc. 2019 Equity Incentive Plan (the “2019 Plan”), to, among other things, increase the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 and modify the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants;
6.To conduct any other business properly brought before the meeting.
|
| 2024-03-21 |
详情>>
业绩披露：
2023年年报每股收益-1.58美元,归母净利润-3003.7万美元,同比去年增长-6.05%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.19美元,归母净利润-2197.6万美元,同比去年增长-2.08%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.79美元,归母净利润-1415.2万美元,同比去年增长-1.25%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.42美元,归母净利润-713.9万美元,同比去年增长-6.25%
|
| 2023-04-28 |
股东大会：
将于2023-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to serve until the next annual meeting of stockholders and their successors are duly elected and qualified.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers.
3.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
4.To approve the Regulus Therapeutics Inc. 2019 Equity Incentive Plan, as amended, to, among other things, increase the number of shares of our common stock authorized for issuance under the plan by 5,000,000 shares.
5.To conduct any other business properly brought before the meeting.
|
| 2023-03-23 |
详情>>
业绩披露：
2022年年报每股收益-1.86美元,归母净利润-2832.3万美元,同比去年增长-1.85%
|
| 2022-11-10 |
财报披露：
美东时间 2022-11-10 盘后发布财报
|
| 2022-06-29 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2022-04-27 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for director named herein to serve until the next annual meeting of stockholders and their successors are duly elected and qualified;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-5 to 1-for-20, with such ratio to be determined in the discretion of our board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion (Proposal 2);
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to reduce, if and only if Proposal 2 is both approved and implemented, the number of authorized shares of our common stock to 300,000,000 shares (Proposal 3);
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
5.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
6.To approve the Regulus Therapeutics Inc. 2022 Employee Stock Purchase Plan (the “2022 ESPP”), pursuant to which 1,291,072 shares of our common stock will be available for sale and issuance to our employees;
7.To approve the authorization to adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 2 or Proposal 6;
8.To conduct any other business properly brought before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for director named herein to serve until the next annual meeting of stockholders and their successors are duly elected and qualified;
2.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To ratify the selection by the Audit Committee of the Board of Directors of Ernst-Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
5.To approve the authorization to adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 2.
6.To conduct any other business properly brought before the meeting.
|
| 2020-04-29 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to serve until the next annual meeting of stockholders and their successors are duly elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020;
4.To conduct any other business properly brought before the meeting.
|
| 2019-07-01 |
股东大会：
将于2019-08-01召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To approve the issuance of securities convertible into and exercisable for the Company’s common stock in connection with a financing transaction;
4.To approve the Regulus Therapeutics Inc. 2019 Equity Incentive Plan;
5.To authorize the adjournment of the annual meeting in order to permit the solicitation of additional proxies if there are not sufficient votes to approve Proposal 3 or Proposal 4 described above at the time of the annual meeting;
6.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2019;
7.To conduct any other business properly brought before the meeting.
|
| 2018-10-04 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2018-09-06 |
股东大会：
将于2018-09-28召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-5 to 1-for-20, with such ratio to be determined in the discretion of our board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion (Proposal 1);
2.To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1;
3.To transact any other business that may be properly brought before the meeting or any continuation, adjournment or postponement thereof.
|
| 2018-04-20 |
股东大会：
将于2018-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified.
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement accompanying this notice;
3.To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers;
4.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2018;
5.To conduct any other business properly brought before the meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2017.
3.To conduct any other business properly brought before the meeting.
|
| 2016-04-22 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1. To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified.
2. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to permit removal of a member of the Board of Directors with or without cause by a majority vote of stockholders.
3. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2016.
4. To conduct any other business properly brought before the meeting.
|
| 2015-04-30 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- 1.To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified.
2.To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2015.
3.To conduct any other business properly brought before the meeting.
|